Literature DB >> 23245703

Gammaherpesvirus latency induces antibody-associated thrombocytopenia in mice.

Michael L Freeman1, Claire E Burkum, Kathleen G Lanzer, Alan D Roberts, Mykola Pinkevych, Asako Itakura, Lawrence W Kummer, Frank M Szaba, Miles P Davenport, Owen J T McCarty, David L Woodland, Stephen T Smiley, Marcia A Blackman.   

Abstract

Human herpesviruses establish lifelong latency. Viral recrudescence can lead to the development of cancers, immunoproliferative disorders, transplantation complications, and thrombocytopenia. Although platelet-specific autoantibodies have been reported in patients infected with the Epstein-Barr virus (EBV), the mechanisms by which thrombocytopenia is induced remain unclear, as do the relative contributions of lytic viral replication and latent viral gene expression. The human gammaherpesviruses are tightly restricted in their ability to infect other mammals, so they are difficult to study in live animal models. Here we show that infection of mice with murine gammaherpesvirus-68 (γHV68), a rodent-specific pathogen closely related to EBV, induces the production of platelet-binding antibodies and causes thrombocytopenia. Infection of antibody-deficient mice does not lead to thrombocytopenia, indicating the platelet decrease is mediated by antibody. Additionally, infection with a latency-null recombinant γHV68 does not induce thrombocytopenia, suggesting factors associated with viral latency drive the infection-induced antibody-mediated thrombocytopenia. These studies describe an important animal model of gammaherpesvirus-induced autoimmune thrombocytopenia and demonstrate that this pathology is mediated by antibody and dependent on viral latency. This model will allow studies of the underlying mechanisms of disease progression and the testing of therapeutic strategies for the alleviation of virus-induced thrombocytopenia.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23245703      PMCID: PMC3608809          DOI: 10.1016/j.jaut.2012.11.005

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  65 in total

Review 1.  Polyclonal B cell activation in infections: infectious agents' devilry or defense mechanism of the host?

Authors:  Carolina L Montes; Eva V Acosta-Rodríguez; Maria Cecilia Merino; Daniela A Bermejo; Adriana Gruppi
Journal:  J Leukoc Biol       Date:  2007-07-05       Impact factor: 4.962

2.  gamma-Herpesvirus-induced protection against bacterial infection is transient.

Authors:  Eric J Yager; Frank M Szaba; Larry W Kummer; Kathleen G Lanzer; Claire E Burkum; Stephen T Smiley; Marcia A Blackman
Journal:  Viral Immunol       Date:  2009-02       Impact factor: 2.257

3.  Postvaccination hyperhemolysis coinciding with remission of Epstein Barr virus (EBV)-associated immune thrombocytopenic purpura (ITP).

Authors:  Christine M Cserti-Gazdewich; Jacob M Pendergrast; Marciano Reis
Journal:  Am J Hematol       Date:  2009-09       Impact factor: 10.047

Review 4.  The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation.

Authors:  Douglas B Cines; Howard A Liebman
Journal:  Hematol Oncol Clin North Am       Date:  2009-12       Impact factor: 3.722

5.  Expansion of effector memory TCR Vbeta4+ CD8+ T cells is associated with latent infection-mediated resistance to transplantation tolerance.

Authors:  Dale Stapler; Eun D Lee; Saranya A Selvaraj; Andrew G Evans; Leslie S Kean; Samuel H Speck; Christian P Larsen; Shivaprakash Gangappa
Journal:  J Immunol       Date:  2008-03-01       Impact factor: 5.422

6.  A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus.

Authors:  Damian M Carragher; Denise A Kaminski; Amy Moquin; Louise Hartson; Troy D Randall
Journal:  J Immunol       Date:  2008-09-15       Impact factor: 5.422

Review 7.  Regulation and dysregulation of Epstein-Barr virus latency: implications for the development of autoimmune diseases.

Authors:  Hans Helmut Niller; Hans Wolf; Janos Minarovits
Journal:  Autoimmunity       Date:  2008-05       Impact factor: 2.815

8.  Infection with murine gammaherpesvirus 68 exacerbates inflammatory bowel disease in IL-10-deficient mice.

Authors:  D A Nelson; C C Petty; Kenneth L Bost
Journal:  Inflamm Res       Date:  2009-06-21       Impact factor: 4.575

9.  Herpesvirus latency confers symbiotic protection from bacterial infection.

Authors:  Erik S Barton; Douglas W White; Jason S Cathelyn; Kelly A Brett-McClellan; Michael Engle; Michael S Diamond; Virginia L Miller; Herbert W Virgin
Journal:  Nature       Date:  2007-05-17       Impact factor: 49.962

10.  A gammaherpesvirus-secreted activator of Vbeta4+ CD8+ T cells regulates chronic infection and immunopathology.

Authors:  Andrew G Evans; Janice M Moser; Laurie T Krug; Veranika Pozharskaya; Ana L Mora; Samuel H Speck
Journal:  J Exp Med       Date:  2008-03-10       Impact factor: 14.307

View more
  4 in total

1.  The challenge of treating orphan disease.

Authors:  Carlos Dias; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 2.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

Review 3.  Dangerous Liaisons: Gammaherpesvirus Subversion of the Immunoglobulin Repertoire.

Authors:  Monika A Zelazowska; Kevin McBride; Laurie T Krug
Journal:  Viruses       Date:  2020-07-23       Impact factor: 5.048

4.  From Superantigens to "Real" Viral Antigens.

Authors:  Marcia A Blackman
Journal:  Viral Immunol       Date:  2020-04       Impact factor: 2.257

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.